Cover Image
市場調查報告書

的醫藥品的預測與市場分析抗藥性金黃色葡萄球菌 (MRSA) - EU5個國家

Methicillin-Resistant Staphylococcus aureus (MRSA) - 5EU Drug Forecast and Market Analysis to 2024

出版商 GlobalData 商品編碼 365837
出版日期 內容資訊 英文 328 Pages
訂單完成後即時交付
價格
Back to Top
的醫藥品的預測與市場分析抗藥性金黃色葡萄球菌 (MRSA) - EU5個國家 Methicillin-Resistant Staphylococcus aureus (MRSA) - 5EU Drug Forecast and Market Analysis to 2024
出版日期: 2015年12月16日 內容資訊: 英文 328 Pages
簡介

本報告提供EU5個國家(法國、德國、義大利、西班牙、英國) 的抗藥性金黃色葡萄球菌 (MRSA) 治療藥市場相關調查分析,疾病概要和治療指南,競爭情形,主要藥物的詳細資訊 (產品說明,安全性,有效性) 、SWOT分析,銷售額預測,影響分析 (趨勢,推動因素、阻礙因素) 等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因
  • 病理生理學
  • 症狀
  • 預後

第4章 疾病的管理

  • 診斷和治療概要
  • EU5個國家
    • 預測
    • 主要的活動
    • 推動因素、障礙

第5章 競爭評估

  • 概要
  • 產品簡介:Glycopeptides,Lipoglycopeptides
  • 產品簡介:Lipopeptides
  • 產品簡介:Oxazolidinones
  • 產品簡介:Cephalosporins
  • 產品簡介:Glycylcyclines
  • 其他抗菌藥

第6章 未滿足需求和機會

  • 概要
  • 有效性
  • 皮膚感染疾病以外的臨床資料
  • 醫生的教育
  • 抗生素
  • 創新的方法
  • 新的作用機制
  • 合理價格的治療

第7章 開發平台評估

  • 概要
  • 臨床開發中 (後期)的有前途藥物
  • 其他臨床開發中的有潛力產品

第8章 市場預測

  • EU5個國家
    • 預測
    • 主要的活動
    • 推動因素、障礙

第9章 附錄

圖表

目錄
Product Code: GDHC287CFR

With the discovery of penicillin, the first naturally-occurring antibiotic, in 1928, and its mass production in the early 1940s, infections with Staphylococcus aureus were mostly treatable, without any major complications. However, clinicians soon observed the emergence of penicillin-resistant strains of S. aureus, which was largely driven by bacterial expression of beta-lactamases. Methicillin, a novel penicillin analogue that was resistant to beta-lactamases, was introduced in 1959, and was initially effective against penicillin-resistant S. aureus strains. However, this success was short-lived, as the first methicillin-resistant S. aureus (MRSA) strain had been identified in the lab by 1961, and cases of MRSA were first observed in the clinic in 1968. Initially, MRSA strains only occurred in small and local outbreaks across the US and Europe, but they can now be found around the world.

For the purposes of this report, GlobalData defines the 5EU MRSA market as encompassing the sales of antimicrobial agents prescribed for the treatment of hospitalized MRSA skin infections, pneumonia, and bacteremia in France, Germany, Italy, Spain, and the UK. Importantly, revenues generated by these products outside of the aforementioned countries, patient populations, and clinical scenarios are beyond the scope of this analysis.

Scope

  • Overview of MRSA including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in 5EU from 2014-2024.
  • Analysis of the impact of key events as well the drivers and restraints affecting 5EU MRSA market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for MRSA.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2014-2024 in 5EU.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology
    • 3.1.1. MRSA Strains
    • 3.1.2. VISA Strains
    • 3.1.3. VRSA Strains
  • 3.2. Pathophysiology
    • 3.2.1. Infection Sites
    • 3.2.2. Expression of Virulence Factors
    • 3.2.3. Mechanisms of Antibiotic Resistance
    • 3.2.4. Biofilm Formation
  • 3.3. Symptoms
  • 3.4. Prognosis
    • 3.4.1. Skin and Soft Tissue Infections
    • 3.4.2. Pneumonia
    • 3.4.3. Bacteremia
    • 3.4.4. Chronic MRSA Infection

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines
    • 4.1.3. Clinical Practice
  • 4.2. 5EU
    • 4.2.1. Forecast
    • 4.2.2. Key Events
    • 4.2.3. Drivers and Barriers

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Product Profiles. Glycopeptides and Lipoglycopeptides
    • 5.2.1. Vancomycin
    • 5.2.2. Dalvance (dalbavancin)
    • 5.2.3. Orbactiv (oritavancin)
    • 5.2.4. Vibativ (telavancin)
    • 5.2.5. Targocid (teicoplanin)
  • 5.3. Product Profiles. Lipopeptides
    • 5.3.1. Cubicin (daptomycin)
  • 5.4. Product Profiles. Oxazolidinones
    • 5.4.1. Zyvox (linezolid)
    • 5.4.2. Sivextro (tedizolid phosphate)
  • 5.5. Product Profiles. Cephalosporins
    • 5.5.1. Teflaro (ceftaroline fosamil)
    • 5.5.2. Zevtera (ceftobiprole medocaril)
  • 5.6. Product Profiles. Glycylcyclines
    • 5.6.1. Tygacil (tigecycline)
  • 5.7. Other Antimicrobial Agents

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. Drugs with Demonstrated Efficacy in Difficult-to-Treat Patient Populations
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Expand Breadth of Clinical Data Outside of Skin Infections
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Physician Education
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Antibiotics with More Convenient Formulations and Dosing Schedules
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity
  • 6.6. Innovative Approaches to Clinical Trial Design
    • 6.6.1. Unmet Need
    • 6.6.2. Gap Analysis
    • 6.6.3. Opportunity
  • 6.7. Drugs with Novel Mechanisms of Action
    • 6.7.1. Unmet Need
    • 6.7.2. Gap Analysis
    • 6.7.3. Opportunity
  • 6.8. More Affordable Therapies
    • 6.8.1. Unmet Need
    • 6.8.2. Gap Analysis
    • 6.8.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Late-Stage Clinical Development
    • 7.2.1. Delafloxacin (RX-3341)
    • 7.2.2. Solithromycin (CEM-101)
    • 7.2.3. Omadacycline (PTK-0796)
    • 7.2.4. KRP-AM1977X
    • 7.2.5. Taksta (fusidic acid, oral tablets)
    • 7.2.6. Lefamulin (BC-3781)
    • 7.2.7. Debio1450(Debio1452 prodrug)
    • 7.2.8. Brilacidin
  • 7.3. Other Promising Products in Clinical Development

8. Market Outlook

  • 8.1. 5EU
    • 8.1.1. Forecast
    • 8.1.2. Key Events
    • 8.1.3. Drivers and Barriers

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Hospitalized MRSA Patients
    • 9.4.2. Percentage of Drug-Treated MRSA Patients
    • 9.4.3. Drugs Included in Each Therapeutic Class
    • 9.4.4. Launch, Label Expansion, and Patent Expiry Dates
    • 9.4.5. General Pricing Assumptions
    • 9.4.6. Individual Drug Assumptions
    • 9.4.7. Generic Erosion
    • 9.4.8. Pricing of Pipeline Agents
  • 9.5. Primary Research. KOLs Interviewed for This Report
  • 9.6. Primary Research. Prescriber Survey
  • 9.7. About the Authors
    • 9.7.1. Author and Therapy Area Director
    • 9.7.2. Author
    • 9.7.3. Epidemiologist
    • 9.7.4. Global Director of Therapy Analysis and Epidemiology
    • 9.7.5. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Disclaimer

List of Tables

  • Table 1: Symptoms of MRSA-Associated Infections
  • Table 2: National and International Treatment Guidelines for MRSA Infections
  • Table 3: Sales Forecasts ($m) for MRSA in the 5EU, 2014-2024
  • Table 4: Key Events Impacting Sales for MRSA in the 5EU, 2014-2024
  • Table 5: MRSA Therapeutics Market - Drivers and Barriers in the 5EU, 2014-2024
  • Table 6: National Healthcare Authorities and Government Drug Pricing Authorities in the 5EU Nations
  • Table 7: Leading Branded Treatments for MRSA, 2015
  • Table 8: Product Profile - Vancomycin
  • Table 9: Vancomycin SWOT Analysis, 2015
  • Table 10: Global Sales Forecasts ($m) for Vancomycin, 2014-2024
  • Table 11: Product Profile - Dalvance
  • Table 12: Efficacy of Dalvance - Primary and Secondary Endpoints, DISCOVER 1 and DISCOVER 2
  • Table 13: Safety of Dalvance - Frequency of AEs, DISCOVER 1 and DISCOVER 2
  • Table 14: Dalvance SWOT Analysis, 2015
  • Table 15: Global Sales Forecasts ($m) for Dalvance, 2014-2024
  • Table 16: Product Profile - Orbactiv
  • Table 17: Efficacy of Orbactiv - Primary and Secondary Endpoints, SOLO I and SOLO II
  • Table 18: Safety of Orbactiv - Frequency of AEs, SOLO I and SOLO II
  • Table 19: Orbactiv SWOT Analysis, 2015
  • Table 20: Global Sales Forecasts ($m) for Orbactiv, 2014-2024
  • Table 21: Product Profile - Vibativ
  • Table 22: Efficacy of Vibativ - Pooled Primary and Secondary Endpoints, ATLAS 1 and ATLAS 2
  • Table 23: Safety of Vibativ - Frequency of AEs, ATLAS and ATTAIN Phase III Programs
  • Table 24: Vibativ SWOT Analysis, 2015
  • Table 25: Global Sales Forecasts ($m) for Vibativ, 2014-2024
  • Table 26: Product Profile - Targocid
  • Table 27: Targocid SWOT Analysis, 2015
  • Table 28: Global Sales Forecasts ($m) for Targocid, 2014-2024
  • Table 29: Product Profile - Cubicin
  • Table 30: Efficacy of Cubicin - Pooled Clinical Success Rates by Causative Pathogen, cSSSI Trials
  • Table 31: Safety of Cubicin - Frequency of AEs and SAEs
  • Table 32: Cubicin SWOT Analysis, 2015
  • Table 33: Global Sales Forecasts ($m) for Cubicin, 2014-2024
  • Table 34: Product Profile - Zyvox
  • Table 35: Efficacy of Zyvox - Primary and Secondary Endpoints, cSSSI Study in Adults
  • Table 36: Safety of Zyvox - Frequency of Treatment-Emergent AEs
  • Table 37: Zyvox SWOT Analysis, 2015
  • Table 38: Global Sales Forecasts ($m) for Zyvox, 2014-2024
  • Table 39: Product Profile - Sivextro
  • Table 40: Efficacy of Sivextro - Primary and Secondary Endpoints, ESTABLISH Phase III Program
  • Table 41: Safety of Sivextro - Frequency of Treatment-Emergent AEs, ESTABLISH-1 and ESTABLISH-2
  • Table 42: Sivextro SWOT Analysis, 2015
  • Table 43: Global Sales Forecasts ($m) for Sivextro, 2014-2024
  • Table 44: Product Profile - Teflaro
  • Table 45: Efficacy of Teflaro - Pooled Primary and Secondary Endpoints, FOCUS 1 and FOCUS 2
  • Table 46: Safety of Teflaro - Frequency of AEs, FOCUS and CANVAS Phase III Programs
  • Table 47: Teflaro SWOT Analysis, 2015
  • Table 48: Global Sales Forecasts ($m) for Teflaro, 2014-2024
  • Table 49: Product Profile - Zevtera
  • Table 50: Efficacy of Zevtera - Primary and Endpoints, HABP and CABP Phase III Studies
  • Table 51: Safety of Zevtera - Frequency of AEs, HABP and CABP Phase III Studies
  • Table 52: Zevtera SWOT Analysis, 2015
  • Table 53: Global Sales Forecasts ($m) for Zevtera, 2014-2024
  • Table 54: Product Profile - Tygacil
  • Table 55: Tygacil SWOT Analysis, 2015
  • Table 56: Global Sales Forecasts ($m) for Tygacil, 2014-2024
  • Table 57: Summary of Other Antimicrobial Agents Used for S. aureus and MRSA, 2015
  • Table 58: Unmet Need and Opportunity in MRSA, 2015
  • Table 59: Key Late-Stage Pipeline Agents for MRSA, 2015
  • Table 60: Product Profile - Delafloxacin
  • Table 61: Delafloxacin SWOT Analysis, 2015
  • Table 62: Global Sales Forecasts ($m) for Delafloxacin, 2014-2024
  • Table 63: Product Profile - Solithromycin
  • Table 64: Solithromycin SWOT Analysis, 2015
  • Table 65: Global Sales Forecasts ($m) for Solithromycin, 2014-2024
  • Table 66: Product Profile - Omadacycline
  • Table 67: Omadacycline SWOT Analysis, 2015
  • Table 68: Global Sales Forecasts ($m) for Omadacycline, 2014-2024
  • Table 69: Product Profile - KRP-AM1977X
  • Table 70: KRP-AM1977X SWOT Analysis, 2015
  • Table 71: Global Sales Forecasts ($m) for KRP-AM1977X, 2014-2024
  • Table 72: Product Profile - Taksta
  • Table 73: Taksta SWOT Analysis, 2015
  • Table 74: Global Sales Forecasts ($m) for Taksta, 2014-2024
  • Table 75: Product Profile - Lefamulin
  • Table 76: Lefamulin SWOT Analysis, 2015
  • Table 77: Global Sales Forecasts ($m) for Lefamulin, 2014-2024
  • Table 78: Product Profile - Debio1450
  • Table 79: Debio1450 SWOT Analysis, 2015
  • Table 80: Global Sales Forecasts ($m) for Debio1450, 2014-2024
  • Table 81: Product Profile - Brilacidin
  • Table 82: Brilacidin SWOT Analysis, 2015
  • Table 83: Global Sales Forecasts ($m) for Brilacidin, 2014-2024
  • Table 84: Other Promising Pipeline Products for MRSA, 2015
  • Table 85: Sales Forecasts ($m) for MRSA in the 5EU, 2014-2024
  • Table 86: Key Events Impacting Sales for MRSA in the 5EU, 2014-2024
  • Table 87: MRSA Therapeutics Market - Drivers and Barriers in the 5EU, 2014-2024
  • Table 88: National Healthcare Authorities and Government Drug Pricing Authorities in the 5EU Nations
  • Table 89: Key Historical and Projected Launch Dates for MRSA Across the 7MM
  • Table 90: Key Historical and Projected Label Expansion Dates for MRSA Across the 7MM
  • Table 91: Key Historical and Projected Patent Expiry Dates for MRSA Across the 7MM
  • Table 92: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: The MRSA SCCmec Gene Cluster
  • Figure 2: Sites of S. aureus Infection
  • Figure 3: Cartoon Depicting the Key Mechanisms of Antibiotic Resistance Observed in S. aureus
  • Figure 4: Sales for MRSA Therapeutics by Drug Class in the 5EU, 2014 and 2024
  • Figure 5: Sales for MRSA Therapeutics by Country in the 5EU, 2014-2024
  • Figure 6: MRSA Therapeutics - Phase III/Phase II Pipeline, 2015
  • Figure 7: Competitive Assessment of the Recently Approved and Late-Stage Pipeline Agents in MRSA, 2014-2024
  • Figure 8: Sales for MRSA Therapeutics by Drug Class in the 5EU, 2014 and 2024
  • Figure 9: Sales for MRSA Therapeutics by Country in the 5EU, 2014-2024
Back to Top